Vanderbilt Ingram Cancer Center Archives
Nov. 15, 2018—Sarah Rohde long had an interest in treating cancer, and her research during her undergraduate and medical school years at the University of Virginia underscored that. What she didn’t expect was to become a surgeon.
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
Nov. 8, 2018—A new grant from the National Cancer Institute (NCI) will fund an intensively mentored training experience for clinical fellows at Vanderbilt University Medical Center for the next five years.
Nov. 2, 2018—Vanderbilt-Ingram Cancer Stem Cell Transplant ranks among the best in the nation for donor stem cell transplant survival rates among large centers, according to an annual report.
Nov. 1, 2018—Stephen Baylin, MD, a trailblazer in the study of the epigenetics of cancer, will deliver the next Flexner Discovery Lecture on Thursday, Nov. 8. His lecture, sponsored by the Vanderbilt-Ingram Cancer Center, will begin at 4 p.m. in room 208 Light Hall.
Oct. 25, 2018—Patients with stage IV small-cell lung cancer lived longer when given the immunotherapy atezolizumab with chemotherapy, setting the stage for what could become the first new treatment approved in decades for this particularly aggressive form of lung cancer.
Oct. 4, 2018—Mia Levy, MD, PhD, director of Cancer Health Informatics and Strategy at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Associate Professor of Cancer Research, has been named director of Rush University Cancer Center and Systems Vice President for Cancer Service at Rush University Medical Center in Chicago.
Oct. 4, 2018—Singer Anita Cochran had famous friends in the room when she celebrated her last cancer treatment, but the person with her who mattered the most was her 89-year-old father.
Sep. 27, 2018—A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.